The study is a multicenter, open label Phase I/II trial. 1.To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2.To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.